The correlation between retinal Cp burden, NLRP3 inflammasome activation, retinal amyloidogenic peptides, brain tauopathy, and disease status underscores the potential for targeting Cp and its associated inflammatory pathways as a therapeutic strategy in AD. This evidence concerns the gene CP and Alzheimer disease.